Susceptibility of Campylobacter pyloridis to three macrolide antibiotics (erythromycin, roxithromycin [RU 28965], and CP 62,993) and rifampin.
The presence of Campylobacter pyloridis in the gastric mucosa was recently linked to peptic ulcer disease. This study compared the inhibitory activity of three macrolide compounds (erythromycin, roxithromycin [RU 28965], and CP 62,993) and rifampin against 10 clinical isolates of C. pyloridis. The macrolides were equally effective against the test strains, with MICs ranging from 0.06 to 0.5 microgram/ml; rifampin was less active, with MICs ranging from 0.25 to greater than 1 microgram/ml. Erythromycin and the two new macrolide derivatives are potentially useful agents in the treatment of infections caused by C. pyloridis.
D000328:Adult; D002167:Campylobacter / Q000187:drug effects*; D004917:Erythromycin / Q000494:pharmacology*; D006801:Humans; D007223:Infant; D007933:Leucomycins / Q000494:pharmacology*; D012293:Rifampin / Q000494:pharmacology*
D007933:Leucomycins; D004917:Erythromycin; D012293:Rifampin